MedTrace Logo

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

NCT05484583 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-08-05

No results posted yet for this study

Summary

In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide scientific basis for the formulation of the best comprehensive treatment plan in the future.

Conditions

  • Lung Cancer
  • Extensive-stage Small-cell Lung Cancer
  • Radiotherapy

Interventions

DRUG

Durvalumab + carboplatin/cisplatin + etoposide

Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip

RADIATION

Consolidation radiotherapy

Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.

DRUG

Durvalumab

Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion

Sponsors & Collaborators

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-08-01
Completion
2027-08-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05484583 on ClinicalTrials.gov